Overall, considering significant elevated CEA levels originating from atypical epithelial proliferation in non-survivors with COVID-19 of our study, we think Nintedanib may be one of therapeutic options for antifibrotic therapy in addition to other basic treatment (oxygen therapy, antiviral therapy etc.)for COVID-19 patients especially those critical cases with elevation of CEA levels. Here, CEACAM5 is linked to COVID-19.